Published in Oncologist on May 31, 2011
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res (2012) 0.99
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy? Oncoimmunology (2015) 0.87
Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology (2012) 0.85
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling. J Cancer (2015) 0.83
Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticancer Ther (2014) 0.82
Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo. Cancer Gene Ther (2014) 0.80
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma. Int J Oncol (2016) 0.77
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist (2016) 0.76
c-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons. Neurochem Res (2017) 0.75
Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene (2014) 0.75
Notch as a tumour suppressor. Nat Rev Cancer (2017) 0.75
Pancreatic body adenocarcinoma with neuroendocrine tumor characteristics: A case report. Oncol Lett (2014) 0.75
NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget (2016) 0.75
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med (2017) 0.75
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
A 5-decade analysis of 13,715 carcinoid tumors. Cancer (2003) 12.78
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer (2003) 4.75
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Current status of gastrointestinal carcinoids. Gastroenterology (2005) 4.26
Carcinoid tumors. Oncologist (2008) 2.86
Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer (1999) 2.46
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res (2004) 1.59
Epidemiology of neuroendocrine tumours. Neuroendocrinology (2004) 1.59
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol (2010) 1.59
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am (2001) 1.29
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
Gastrointestinal neuroendocrine tumors. J Am Coll Surg (1994) 1.21
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol (2001) 1.13
Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion (2000) 1.12
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis (2006) 1.08
The history of valproate in clinical neuroscience. Psychopharmacol Bull (2003) 1.06
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res (2010) 1.01
Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology (2008) 0.96
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer (2004) 0.94
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol (2004) 0.87
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story? Acta Gastroenterol Belg (2009) 0.79
Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors. Cancer Treat Res (1997) 0.79
In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. Proc Natl Acad Sci U S A (2007) 4.53
Carcinoid tumors. Oncologist (2008) 2.86
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2007) 2.26
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg (2013) 2.10
In vivo multiphoton fluorescence lifetime imaging of protein-bound and free nicotinamide adenine dinucleotide in normal and precancerous epithelia. J Biomed Opt (2007) 2.09
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg (2013) 1.96
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid (2013) 1.77
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 1.64
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol (2007) 1.56
Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56
Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics (2009) 1.56
The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol (2004) 1.53
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
School-based fitness changes are lost during the summer vacation. Arch Pediatr Adolesc Med (2007) 1.51
25-hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol (2010) 1.50
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol (2010) 1.49
Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol (2014) 1.48
Can thallium-pertechnetate subtraction scanning play a role in the preoperative imaging for minimally invasive parathyroidectomy? Clin Nucl Med (2004) 1.47
Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol (2006) 1.46
Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid (2012) 1.46
Carcinoid tumors. Surg Oncol Clin N Am (2006) 1.45
Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database. Cancer (2012) 1.45
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. Surgery (2009) 1.42
The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg (2011) 1.42
Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. J Surg Res (2009) 1.42
All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41
How Well Does Renal Transplantation Cure Hyperparathyroidism? Ann Surg (2015) 1.40
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg (2008) 1.39
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study. Clin Adv Hematol Oncol (2011) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am (2009) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) (2008) 1.31
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer. Clin Lung Cancer (2008) 1.26
Surgery for primary hyperparathyroidism: what is the best approach? Ann Surg (2002) 1.26
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res (2005) 1.23
Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg (2006) 1.22
Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res (2002) 1.22
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg (2009) 1.20
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol (2009) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg (2009) 1.17
Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery (2012) 1.17
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Medical student operative experience correlates with a match to a categorical surgical program. Am J Surg (2003) 1.15
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res (2011) 1.15
Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol (2012) 1.14
Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat (2006) 1.14
Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery (2010) 1.14
Contralateral papillary thyroid cancer: does size matter? Am J Surg (2009) 1.14
Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res (2009) 1.13
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism. Surgery (2003) 1.12
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol (2009) 1.12
Why do students choose careers in surgery? J Surg Res (2004) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab (2010) 1.11
Fitness is a stronger predictor of fasting insulin levels than fatness in overweight male middle-school children. J Pediatr (2007) 1.10
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol (2012) 1.10
Parathyroid hormone deficiency after total thyroidectomy: incidence and time. J Surg Res (2010) 1.10
Calciphylaxis in the absence of end-stage renal disease. Endocr Pract (2006) 1.09
New trends in parathyroid surgery. Curr Probl Surg (2010) 1.09
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res (2011) 1.08
The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 1.08
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid (2011) 1.08
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs (2008) 1.08